Clinical trials: Community-acquired Pneumonia (CAP)
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
- Trial name
- LEAP (NCT02559310)
- Testing
- lefamulin, Moxifloxacin, Linezolid
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 551 people
- Sponsor
- Nabriva Therapeutics AG
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
A Global Active Surveillance for Community Acquired Pneumonia
This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia.
- Trial name
- NCT00929721
- Testing
- Blood draw, Chest X-ray, urine specimen
- Where
- Poland
- Volunteers
- 5,172 people
- Sponsor
- Pfizer
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
The main purpose of this study is to use an investigational urine assay to estimate the proportion of pneumonia in adults 50 years or older in different areas throughout the US that is caused by certain types of the bacteria…
- Trial name
- NCT01086397
- Testing
- Urine sample collection
- Where
- 14 sites in United States
- Volunteers
- 782 people
- Sponsor
- Pfizer
COVID-19, Undefined
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired…
- Trial name
- NCT04659122
- Testing
- AT-100
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Airway Therapeutics, Inc.
Pneumonia
Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia
The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5-7 days in children with community-acquired pneumonia (CAP).
- Trial name
- NCT00638859
- Testing
- Telithromycin (HMR3647)
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Sanofi
Pneumococcal Disease
Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.
Serotype distribution and estimation of antimicrobial resistance in S. pneumoniae isolates and anticipated PCV7 and PCV13 coverage is difficult in Greece, because invasive isolates collected each year are limited and depict a…
- Trial name
- B1851065 (NCT01564771)
- Testing
- Non Intervention
- Where
- 21 sites in Greece
- Volunteers
- 293 people
- Sponsor
- Pfizer
Community-Acquired Pneumonia
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response.
- Trial name
- NCT00140023
- Testing
- Azithromycin microspheres 2.0 single dose
- Where
- 5 sites in Philippines
- Volunteers
- 47 people
- Sponsor
- Pfizer
Pneumonia
Community-Acquired Pneumonia (CAP) Surveillance
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.
- Trial name
- NCT01416506
- Testing
- No Drug
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Bayer
Pneumonia, Bacterial
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan.
- Trial name
- NCT01189487
- Testing
- ampicillin sodium/sulbactam sodium
- Where
- 22 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Pfizer
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Community-Acquired Pneumonia (CAP)
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia…
- Trial name
- NCT06782282
- Where
- United States
- Volunteers
- 22,234,435 people
- Sponsor
- Pfizer
Community-acquired Pneumonia
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Through a series of retrospective analysis, it is hoped that an objective evaluation of the effect and safety of Eucalyptol, Limonene and Pinene Enteric Soft Capsules in the treatment of community-acquired pneumonia can be made.
- Trial name
- NCT05002192
- Testing
- Eucalyptol, Limonene and Pinene Enteric Soft Capsule, Ambroxol injection, Other oral mucolytic drugs
- Where
- 7 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Grand Johamu Pharmaceutical Company, Ltd.
Community-Acquired Pneumonia
Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia
This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia(CAP)
- Trial name
- NCT00434291
- Testing
- TG-873870(Nemonoxacin)
- Where
- 20 sites in South Africa, Taiwan
- Volunteers
- 264 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336505
- Testing
- Cethromycin, Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 584 people
- Sponsor
- Advanced Life Sciences, Inc.
Community Acquired Pneumonia (CAP), Complicated Skin and Skin Structures Infections (cSSSI)
Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections
This study will collect real-life data from patients with community acquired pneumonia (CAP) OR complicated skin and skin structure infections (cSSSI) to assess the burden of the disease, review the treatment pathways, evaluate…
- Trial name
- REACH (NCT01293435)
- Where
- 163 sites in Belgium, France and 8 more
- Volunteers
- 4,035 people
- Sponsor
- AstraZeneca
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Community Acquired Pneumonia
Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults
- Trial name
- NCT00653172
- Testing
- NXL103, comparator
- Where
- 60 sites in Chile, Croatia and 7 more
- Volunteers
- 302 people
- Sponsor
- Novexel Inc